GEAP202416520A - Formulations - Google Patents

Formulations

Info

Publication number
GEAP202416520A
GEAP202416520A GEAP202416520A GEAP2024016520A GEAP202416520A GE AP202416520 A GEAP202416520 A GE AP202416520A GE AP202416520 A GEAP202416520 A GE AP202416520A GE AP2024016520 A GEAP2024016520 A GE AP2024016520A GE AP202416520 A GEAP202416520 A GE AP202416520A
Authority
GE
Georgia
Prior art keywords
formulations
scopes
histidine
antibody
preparing
Prior art date
Application number
GEAP202416520A
Other languages
English (en)
Inventor
Michaёl Joseph Edouard Boonen
Claude Peerboom
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of GEAP202416520A publication Critical patent/GEAP202416520A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GEAP202416520A 2021-10-21 2022-10-20 Formulations GEAP202416520A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2115121.2A GB202115121D0 (en) 2021-10-21 2021-10-21 Formulations

Publications (1)

Publication Number Publication Date
GEAP202416520A true GEAP202416520A (en) 2024-07-25

Family

ID=78806158

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202416520A GEAP202416520A (en) 2021-10-21 2022-10-20 Formulations
GEAP202216520A GEP20257800B (en) 2021-10-21 2022-10-20 Formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202216520A GEP20257800B (en) 2021-10-21 2022-10-20 Formulations

Country Status (17)

Country Link
US (1) US20240415769A1 (https=)
EP (1) EP4419078A1 (https=)
JP (1) JP2024539265A (https=)
KR (1) KR20240099311A (https=)
CN (1) CN118119377A (https=)
AR (1) AR127421A1 (https=)
AU (1) AU2022372646A1 (https=)
CA (1) CA3235381A1 (https=)
CL (1) CL2024001229A1 (https=)
CO (1) CO2024006193A2 (https=)
GB (1) GB202115121D0 (https=)
GE (2) GEAP202416520A (https=)
IL (1) IL312207A (https=)
MX (1) MX2024004872A (https=)
PE (1) PE20241193A1 (https=)
TW (1) TW202323288A (https=)
WO (1) WO2023067049A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
AU2022372646A1 (en) 2024-06-06
AR127421A1 (es) 2024-01-24
GB202115121D0 (en) 2021-12-08
GEP20257800B (en) 2025-09-25
CN118119377A (zh) 2024-05-31
JP2024539265A (ja) 2024-10-28
TW202323288A (zh) 2023-06-16
CA3235381A1 (en) 2023-04-27
KR20240099311A (ko) 2024-06-28
US20240415769A1 (en) 2024-12-19
MX2024004872A (es) 2024-05-06
PE20241193A1 (es) 2024-06-03
IL312207A (en) 2024-06-01
EP4419078A1 (en) 2024-08-28
CL2024001229A1 (es) 2024-09-13
CO2024006193A2 (es) 2024-05-30
WO2023067049A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
PH12018501525A1 (en) Tgfbeta 2 antibodies
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
TN2018000341A1 (en) ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
WO2017053807A3 (en) Optimized variants of anti-vegf antibodies
MX2021001550A (es) Inhibidores de transglutaminasa 2 (tg2).
PH12022552371A1 (en) Anti-interleukin-33 antibodies and uses thereof
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
SA520420287B1 (ar) مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
MA48939B1 (fr) Compositions comprenant des souches bactériennes
WO2021118930A3 (en) Anti-pd-l1 antibody formulations
MY199876A (en) Anti-pacap antibody
MX2025000643A (es) Nanomateriales que comprenden trioles
WO2018189661A3 (en) Methods and compounds for treating diabetes
NZ811397A (en) Liquid tasimelteon formulations and methods of use thereof
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
ZA202006216B (en) Antibodies targeting glycoprotein vi
MA52217B1 (fr) Variants d'anticorps anti-c-terminal